GGrantIndex
← Leaderboards

Jody Corey-Bloom

University Of California San Diego

$3,079,845
Attributed
$3,079,845
Total exposure
19
Grants
19
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $265.4K · FY200518
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$3,079,845 · 19

By mechanism

P50$2,712,268 · 3
M01$367,577 · 16

Top collaborators

No co-investigators on record.

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Resources

Research focus

ResourcesResearch PersonnelClinical ResearchSourceFundingUnited States National Institutes Of HealthInstitutionGrantComputer Retrieval Of Information On Scientific Projects DatabaseCaregiversTrainingResearch StudyHuntington DiseaseDementiaAlzheimer&AposSkillsS DiseaseProgramsPhysiciansCommunitiesElderlyHealth ProfessionalHispanicsSupport Groups

Grant awards (33)

Outreach, Recruitment and Education Core$225,736
P50 · FY2018 · AG · contact PI
Outreach, Recruitment and Education Core$225,818
P50 · FY2017 · AG · contact PI
Outreach, Recruitment and Education Core$214,762
P50 · FY2016 · AG · contact PI
Outreach, Recruitment and Education Core$209,538
P50 · FY2015 · AG · contact PI
Outreach, Recruitment and Education Core$214,762
P50 · FY2014 · AG · contact PI
Education and Information Transfer Core E$166,815
P50 · FY2013 · AG · contact PI
Education and Information Transfer Core E$188,984
P50 · FY2012 · AG · contact PI
Education and Information Transfer Core E$178,243
P50 · FY2011 · AG · contact PI
Education and Information Transfer Core E$180,009
P50 · FY2010 · AG · contact PI
CLINICAL TRIAL: ACR16 VERSUS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON$14,497
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)$11,736
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY OF DIMEBON IN PATIENTS WITH MILD-TO-MODERATE HUNTI$6,385
M01 · FY2010 · RR · contact PI
FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE$3,107
M01 · FY2010 · RR · contact PI
Education and Information Transfer Core E$176,500
P50 · FY2009 · AG · contact PI
CLINICAL TRIAL: A MULTICENTER PHASE 1-2A STUDY OF DIMEBON IN SUBJECTS WITH HUNTI$32,838
M01 · FY2009 · RR · contact PI
FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE$20,382
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)$19,817
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ACR16 VS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON'S D$15,852
M01 · FY2009 · RR · contact PI
CORE--EDUCATION AND INFORMATION TRANSFER$169,465
P50 · FY2008 · AG · contact PI
CLINICAL TRIAL: A MULTICENTER PHASE 1-2A STUDY OF DIMEBON IN SUBJECTS WITH HUNTI$44,421
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)$8,243
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TRIAL OF ETHYL-EPA IN SUBJECTS WITH MILD TO MODERATE HUNTINGTON'$457
M01 · FY2008 · RR · contact PI
CORE--EDUCATION AND INFORMATION TRANSFER$173,785
P50 · FY2007 · AG · contact PI
DETERMINE THE SAFETY AND TOLERABILITY OF PHENYLBUTYRATE IN HUNTINGTON'S DISEASE$14,341
M01 · FY2007 · RR · contact PI
A MULTICENTER PHASE 1-2A STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON'S DISEASE$5,814
M01 · FY2007 · RR · contact PI
TRIAL OF ETHYL-EPA IN SUBJECTS WITH MILD TO MODERATE HUNTINGTON'S DISEASE$387
M01 · FY2007 · RR · contact PI
CORE--EDUCATION AND INFORMATION TRANSFER$132,199
P50 · FY2006 · AG · contact PI
DETERMINE THE SAFETY AND TOLERABILITY OF PHENYLBUTYRATE IN HUNTINGTON'S DISEASE$25,752
M01 · FY2006 · RR · contact PI
SHORT TERM EFFECTS OF MEDICINAL CANNABIS ON SPASTICITY IN MULTIPLE SCLEROSIS$15,242
M01 · FY2006 · RR · contact PI
CORE--EDUCATION AND INFORMATION TRANSFER$129,255
P50 · FY2005 · AG
SHORT TERM EFFECTS OF MEDICINAL CANNABIS ON SPASTICITY IN MULTIPLE SCLEROSIS$78,149
M01 · FY2005 · RR
CORE--EDUCATION AND INFORMATION TRANSFER$126,397
P50 · FY2004 · AG
Short Term Effects of Medicinal Cannabis on MS$50,157
M01 · FY2004 · RR